1. Introduction {#sec1}
===============

Hyperemesis gravidarum (HG), the most severe form of pregnancy-associated nausea and vomiting, is leading to weight loss, nutritional deficiencies, and metabolic disturbance, for example, dehydration, acidosis from starvation, hypokalemia, and transient hepatic dysfunction, often requiring hospitalization and medical treatment to avoid life-threatening complications \[[@B1]\]. HG complicates 0.3--2% of all pregnancies and is a multifactorial disease; however, little is known about the etiology of HG. But a variety of mechanisms may play a role in this disease, such as endocrine factors like human chorionic gonadotropin (HCG), estradiol, and progesterone and immunologic factors, as well as personal factors in which increased body weight has been proposed as possible underlying cause \[[@B2]\]. Recently, several studies have put emphasis on the correlation between*Helicobacter pylori*(*H. pylori*) infection and the risk of HG \[[@B3]--[@B6]\].

*H. pylori*, as a gram-negative flagellated spiral bacterium, colonizes stomach and creates the basis of pathogenesis of gastric pathologies, including chronic gastritis, duodenal and gastric ulcers, gastric adenocarcinoma, and mucosa-associated lymphoid tissue lymphoma \[[@B7]--[@B9]\].*H. pylori* infected the stomach of 50% of the world population, and it is more prevalent in developing countries \[[@B10]\]. The prevalence of*H. pylori*infection in pregnant women varies according to socioeconomic conditions, geographic area, and even the method used to test*H. pylori* infection.

Several studies have shown a possible involvement of*H. pylori* infection in individuals with HG; however, other studies did not share with them. Although three previous meta-analyses have shown the positive association between*H. pylori* and HG, the role of*H. pylori* infection in the pathogenesis of HG has not reached a consensus. Moreover, the previous meta-analyses did not use the comprehensive search method, unable to include the overall studies, and did not perform a detailed analysis on subgroup to explore the potential factors in HG. On the other hand, the role of some factors such as different populations, geographic areas, ethnicity, and low socioeconomic status is unclear in HG. Therefore, our meta-analysis was undertaken to strengthen the hypothesis that*H. pylori* is a risk factor of HG and to describe the underlying factors in HG.

2. Materials and Methods {#sec2}
========================

2.1. Data Sources {#sec2.1}
-----------------

We systematically identified studies in PubMed, Embase, and Web of Science (inception through March 20, 2014) databases by two independent investigators (LL and LLL) for all relevant literatures between the risk of HG and the infection of*H. pylori*, by using the MeSH terms, "*Helicobacter pylori*" OR "*H. pylori*" OR "*Helicobacter*infection" AND "hyperemesis gravidarum." These were searched both as thesaurus terms and as text words. Even "nausea and vomiting" as text word was searched too. Finally, a Google Scholar search was done. Moreover, the references at the end of selected papers were also examined for additional relevant studies.

2.2. Inclusion Criteria {#sec2.2}
-----------------------

In our meta-analysis, the included articles had to meet the following criteria: (1) they must be case-control studies or prospective studies or cross-sectional studies; (2) studies must refer to the association of*H. pylori*infection with HG risk and must provide raw data on*H. pylori* infection in both HG and control groups; (3) the participants must have had a clinical diagnosis of hyperemesis gravidarum as follows: pernicious vomiting, weight loss, and at least one positive ketonuria; (4) the confirmation of*H. pylori* infection was detected by enzyme-linked immunosorbent assay (ELISA), stool antigen test, ^13^C-urea breath test (^13^C-UBT), mucosal biopsy, and polymerase chain reaction (PCR). At least one positive result was considered as confirmation of infection.

2.3. Exclusion Criteria {#sec2.3}
-----------------------

We excluded studies as follows: (1) reports without control groups; (2) reviews and duplicated publications; (3) studies in which the source of*H. pylori* infection in cases and control subjects and other essential information were not offered; hyperthyroidism, multiple gestation trophoblastic neoplasia, gastrointestinal and hepatic disorders, urinary tract or other infections, psychosocial or any other maternal disorders, and any treatment with antacids or antibiotics within the previous 7 days were excluded as well.

2.4. Data Extraction {#sec2.4}
--------------------

According to the inclusion criteria, data was carefully extracted independently by two reviewers (LL and LLL). For each study analyzed, we collected data including first author, year of publication, country of the population studied, study design, sources of pregnant women (primipara or multipara), gestational age, diagnosis of hyperemesis gravidarum, methods of*H. pylori*detection, total number of persons in cases and controls, and the numbers of*H. pylori-*positive and*H. pylori*-negative patients in the HG group and the control group of each study which were recorded, respectively. For conflicting evaluations, an agreement was reached by consensus and agreement with another reviewer (XYZ), referring back to the original articles.

2.5. Statistical Analysis {#sec2.5}
-------------------------

We used pooled odds ratio (OR) with its corresponding 95% confidence interval (CI) to estimate the strength of the association between HG and*H. pylori*infection. Post hoc subgroup analyses were also performed to explain the heterogeneity in results. Subgroups were explored as follows: detection of*H. pylori*infection (serum*H. pylori* IgG/IgM/IgA antibody by ELISA, stool antigen test, mucosal biopsy from endoscopy, or*H. pylori* genome by PCR), publication period (1996--2000, 2001--2005, 2006--2010, or 2011--2014), and region (Asia, North America, Europe, Africa, or Oceania).

The heterogeneity of the studies included in this meta-analysis was assessed using the *Q* statistic test and the *I* ^2^ statistic test. The random-effects model was selected when *P* value \< 0.1 or *I* ^2^ \> 50%; otherwise, the fixed-effects model was selected. Possible publication bias was evaluated by visual inspection of funnel plots and application of Begg\'s and Egger\'s test \[[@B11]--[@B15]\]. *P* values of less than 0.05 from Egger\'s test were considered statistically significant.

All statistical analyses were done with STATA statistical software package version 12.0 (2000; STATA Corp., College Station, TX, USA); *P* \< 0.05 was identified as statistically significant.

3. Results {#sec3}
==========

3.1. Literature Search {#sec3.1}
----------------------

As shown in [Figure 1](#fig1){ref-type="fig"}, after rigorous searching, we identified 104 citations. Of these, fifty-six irrelevant papers were excluded after screening the titles. In the remaining 48 articles, 16 studies included five studies without control group, two did not provide sufficient data, and 9 reviews or meta-analyses were discarded. Thus, a total of thirty-two studies included twenty-nine case-control studies and three cross-sectional studies published between 1998 and 2014 fulfilled our inclusion criteria and were included in the meta-analysis \[[@B3]--[@B6], [@B16]--[@B43]\].

3.2. Characteristics of Included Studies {#sec3.2}
----------------------------------------

With respect to the*H. pylori* detection methods, serum*H. pylori* IgG/IgM/IgA antibody was detected by ELISA in twenty-nine, one, and one studies, respectively. However,*H. pylori* stool antigen (HpSA) was used in seven articles,*H. pylori* genome by PCR (Hp PCR DNA) tested in two studies, and biopsy and histological examination from endoscopy in one literature. Taking into account publication period, five studies were published from 1996 to 2000, twelve researches were from 2001 to 2005, eight studies were from 2006 to 2010, and seven articles were from 2011 to 2014. In addition, in terms of region, twenty studies were from Asian countries (Turkey, Iran, Japan, and China were grouped in Asia according to similarities in geographic position and racial traits), five from North America (USA, Canada, and Puerto Rico were grouped in North America according to similarities in geographic location and racial traits), three from Europe (Norway and Greece were grouped in Europe according to similarities in geographic position and racial traits), three from Africa, and one from Oceania. Apparently, all studies used hospital-based controls. All of the studies followed a standard definition of HG excluding subjects with differential diagnosis such as infections, gastrointestinal and endocrine diseases, or psychiatric illness.

3.3. Overall {#sec3.3}
------------

Thirty-two articles published between 1998 and 2014 met the inclusion criteria and their characteristics were shown in Tables [1](#tab1){ref-type="table"} and [2](#tab2){ref-type="table"} in detail. In total, thirteen studies found no association between*H. pylori* infection and the risk of HG \[[@B12], [@B18], [@B20], [@B26], [@B27], [@B32]--[@B34], [@B36], [@B38], [@B41]--[@B43]\]. However, nineteen researches suggested*H. pylori* infection during pregnancy might be a risk factor for pregnant women with HG \[[@B3]--[@B6], [@B16], [@B17], [@B19], [@B21], [@B23]--[@B25], [@B28]--[@B31], [@B35], [@B37], [@B39], [@B40]\]. All included studies contained a total sample size of 4113 patients and contained 1851 HG cases and 2262 controls, with a total*H. pylori* infection rate of 56.7% (2334/4113). Of the HG cases, 1289 (69.6%) were*H. pylori*-positive; however, 1045 (46.2%) were*H. pylori*-positive in control group. Since overall *I* ^2^ was 81.5%, we used the random-effects model for our analysis. As shown in [Figure 2](#fig2){ref-type="fig"}, the overall OR was 3.34 (95% CI: 2.32--4.81) and the overall effect *Z* value was 6.51 (*P* \< 0.001), which indicated that there was a powerful association between*H. pylori* infection and risk of HG.

3.4. Subgroup Analysis {#sec3.4}
----------------------

To evaluate the underlying confounding factors that may have impacted the overall results, we further conducted subgroup analyses based on detection of*H. pylori* infection, publication period, and region, respectively. Since *I* ^2^ were 0 in subgroups of Hp PCR DNA test and Africa, we selected the fixed-effects model. In the remaining subgroups, *I* ^2^ were \>50%, so the random-effects models were used. As shown in [Table 3](#tab3){ref-type="table"}, ORs of serum*H. pylori* IgM/IgA antibody test by ELISA were 7.77 (95% CI: 0.43--140.84) and 1.32 (95% CI: 0.56--3.12), respectively, which suggested that there was no association between*H. pylori* and HG. However, serum*H. pylori* IgG antibody test by ELISA (OR = 3.32, 95% CI: 2.28--4.84), HpSA test (OR = 1.88, 95% CI: 1.33--2.65), and Hp PCR DNA test (OR = 5.87, 95% CI: 2.47--13.93) reflected*H. pylori* infection was a risk factor of HG. In addition, method of histological examination from endoscopy also showed a positive correlation between*H. pylori* infection and HG (OR = 19.0, 95% CI: 1.79--201.68). With respect to publication period, studies from 1996 to 2000 (OR = 3.66, 95% CI: 1.17--11.48), 2001 to 2005 (OR = 3.89, 95% CI: 2.10--7.21), 2006 to 2010 (OR = 2.01, 95% CI: 1.15--3.49), and 2011 to 2014 (OR = 4.41, 95% CI: 1.72--11.29) all showed significantly high rates of*H. pylori* infection in pregnant women with HG compared to those with normal pregnancy ([Table 3](#tab3){ref-type="table"}). In the subgroup of region, shown in [Table 3](#tab3){ref-type="table"}, compared to those studies in North America (OR = 2.33, 95% CI: 0.63--8.62) and Europe (OR = 1.55, 95% CI: 0.83--2.91), researches of Asia (OR = 3.27, 95% CI: 2.18--4.91), Africa (OR = 12.38, 95% CI: 7.12--21.54), and Oceania (OR = 10.93, 95% CI: 5.22--22.85) reflected*H. pylori* was positively related to HG.

3.5. Bias Diagnostics {#sec3.5}
---------------------

Begg\'s test was created for assessment of possible publication bias ([Figure 3](#fig3){ref-type="fig"}). The *P* values for Egger\'s tests were *P* = 0.067 (*P* \> 0.05), indicating the absence of heterogeneity and implying that the results of the present meta-analysis were relatively stable and that the publication bias might exert little influence on the overall results.

4. Discussion {#sec4}
=============

4.1. Main Findings {#sec4.1}
------------------

This updated meta-analysis suggests that exposure to*H. pylori* is associated with an increased risk of HG. The studies included in this meta-analysis, containing 1851 HG patients of which 1289 cases were confirmed with*H. pylori* infection, implied that the rate of*H. pylori* infection was much greater in HG patients (1289/1851) than that in non-HG patients (1045/2262) after adjusting for confounding variables (*P* \< 0.001).

Our meta-analysis contained 32 articles including 29 case-control studies and 3 cross-sectional articles, which contained comprehensive articles and added new primary studies. We enrolled much more patients with HG (1851) and controls (2262) than those in published studies to further confirm this relationship. We separated subgroups in detection of*H. pylori*infection, publication period, and region to comprehensively evaluate the underlying confounding factors that may have impacted the overall results. As reported before, three previous articles reported similar meta-analysis results \[[@B44]--[@B46]\]. Golberg et al. \[[@B44]\] performed a meta-analysis of 14 studies and did subgroup analysis only on markers of*H. pylori* infection, which suggested that the association might be possible if testing methods for active*H. pylori* infection used nonserological methods. However, our meta-analysis showed that the serological method such as*H. pylori* IgG antibody test was relatively credible. Sandven et al. \[[@B45]\] included 25 case-control studies containing 1455 HG and 1970 controls and carried out subgroups analyses on matched design with nonmatched design and Turkish population with other population. We separated subgroup analyses of region according to Asia, North America, Europe, Africa, or Oceania as described above. Niemeijer et al. \[[@B46]\] performed a systematic review to summarize evidence on biomarkers of HG and their value in diagnosis and estimating disease severity and carried out a diagnostic meta-analysis of 19 studies on*H. pylori* IgG, which showed a sensitivity of 73% and a specificity of 55% in the diagnosis of HG as compared to controls without HG. Our study paid attention not only to the detection method of*H. pylori* IgG, but also to the methods of Hp PCR DNA and HpSA. We also described other detection methods used in pregnant women.

With respect to detection methods used in pregnant women, Hp PCR DNA test seemed much more efficient than ELISA test of serum*H. pylori* IgG antibody, and the latter was more reliable than HpSA test. Of note, Cevrioglu et al. \[[@B30]\] collected both serum and feces samples from pregnant women with HG to investigate specific antibodies for*H. pylori*(immunoglobulin-IgG, IgA) and HpSA, and only HpSA test suggested significant association between*H. pylori* infection and HG while serologic assessment failed to reflect the association (40% versus 12.4%, *P* \< 0.001). By using PCR with specimen of saliva, Güngören et al. \[[@B42]\] found a positive relationship between the symptoms of HG and*H. pylori* positivity, while test of*H. pylori* IgG/IgM antibody failed to detect this association between the symptoms of HG and*H. pylori* positivity. From biopsies of the gastric antrum and corpus, Bagis et al. \[[@B23]\] found that, compared to controls, HG patients were detected with higher*H. pylori* density, degree of inflammation, and*H. pylori* activation, implying that*H. pylori* density might be related to HG since the bacterium density of controls was lower. These results suggested that the degree of gastric complaints might be related to density of*H. pylori*.

In addition, two studies from New Zealand indicate that incidence of hyperemesis gravidarum differs according to women\'s ethnic origin \[[@B47], [@B48]\]. Just as shown in our subgroup analysis of region, studies in North America and Europe suggested no association between*H. pylori* infection and risk of HG, while in Asia, Africa, and Oceania analysis indicated*H. pylori* infection was a risk factor of HG, especially in Africa. Sandven et al. \[[@B39]\] also found this association between*H. pylori* infection and HG was much stronger in Africans as compared to non-Africans. This might be explained by ethnicity and low socioeconomic status.*H. pylori*-infected Africans possibly carry an aggressive variant of the bacterium and the host immune mechanisms might be a key to different responses to*H. pylori* in different populations and geographic areas. As well documented, the prevalence rate of*H. pylori* infection is much higher in developing countries than that in developed countries \[[@B49]--[@B51]\]. As Eshraghian reviewed, the overall prevalence of*H. pylori* infection in Iran and other Eastern Mediterranean Regional Office countries such as Egypt and Afghanistan, irrespective of time and age group, ranged from 30.6% to 82% and ranged from 22% to 87.6%, respectively. However the*H. pylori*prevalence in North Africa was 76% \[[@B52]\]. The prevalence is high in developing countries, while pregnant women with HG in these countries have higher rate of*H. pylori*infection. For example, it is 50%--70% in Turkey \[[@B53]\], more than 80% in Egypt \[[@B54]\]. The above studies all suggested that*H. pylori*infection was a risk factor of HG. Strategies to improve sanitary facilities, educational status, and socioeconomic status should be implemented to minimize*H. pylori* infection and come into the result of decline prevalence of HG.

Our meta-analysis suggested that*H. pylori*infection was a risk factor of HG. Frigo et al. suggested that the*H. pylori*may contribute to its persistence beyond the normal time course \[[@B16]\]. It was once reported that HG was an oxidative stress condition induced by increasing reactive oxygen species (ROS) activity and decreasing antioxidant status \[[@B55]\]. Meanwhile,*H. pylori* colonizes gastric mucosa and generates ROS as well as downregulating levels of plasma antioxidants such as ascorbic acid \[[@B7]\], similar to Güney et al. \[[@B37]\] who found that, compared to the control, level of serum malondialdehyde (MDA) was significantly higher and activities of antioxidant enzymes such as superoxide dismutase (SOD), catalase (CT), and glutathione peroxidase (GSH-Px) were significantly lower in the HG group (*P* \< 0.01). Therefore, they hypothesized that increased ROS activity or decreased antioxidant potential, possibly induced by*H. pylori*, might have a pathogenic role in HG. To date, however, the knowledge of how*H. pylori* causes HG is still very limited, and we assumed the following. Firstly, hormonal mechanisms, in the early phase of pregnancy, as a result of the elevated steroid and human chorionic gonadotropin (HCG) levels, accumulation of fluid, and a displacement of intracellular and extracellular volume occur which in turn leads to a shift in pH in the gastrointestinal tract during pregnancy \[[@B40], [@B57]\]. Secondly, emotional factors, the moods of pregnant women change frequently due to the changes of endocrine hormones that might increase women\'s susceptibility to infection caused by altered cell-mediated immunity that causes changes of various classes of antibodies during different gestational periods \[[@B58], [@B59]\]. Thirdly,*H. pylori* infection might be one potential reason for HG. Dysmotility of gastrointestinal tract and prolonged gastric emptying and intestinal transit time induced by pregnancy might favor infectionof*H. pylori* \[[@B57], [@B59]\]. On the other side, host inflammation response to varies of virulence of*H. pylori*strains also different from each other. The virulence of the organism might be another factor creating a possible link between*H. pylori*and the precipitation of HG. As we all know, cytotoxin-associated gene A product (CagA) and vacuolating cytotoxin A (VacA) are used as markers for genomic diversity of*H. pylori*. In Western countries VacA, rather than CagA, was associated with more severe diseases, while in East Asian countries it is the opposite \[[@B60]--[@B62]\]. Similarly, as shown in [Table 4](#tab4){ref-type="table"}, Xia et al. in Asia (OR = 13.96, 95% CI: 6.56--29.71) found that prevalence of*H. pylori*infection with CagA was positively correlated with HG \[[@B29]\]. Nevertheless Perez-Perez et al. in USA \[[@B18]\] failed to find that CagA plays a role in HG. To date, Vikanes et al. \[[@B43]\] conducted the first case-control study to examine the relationship between*H. pylori* and HG by both CagA and VacA seropositivity in Norway and their results suggested that CagA and VacA seropositivity were not significantly associated with HG. So the role of CagA and VacA in the pathopoiesis of HG was still unclear, and no more studies were performed to explore this relationship. It suggested that study of CagA and VacA might be generalized and probably aim at the populations with high prevalence rate of*H. pylori*infection.

On the other hand, eradication of*H. pylori* could relieve the symptoms of HG. Strachan et al. reported a case of eradication in a 38-year-old woman in her third pregnancy, who orally omeprazole 20 mg bid, metronidazole 400 mg bid, and amoxicillin 500 mg tid for 7 days in her 30 weeks of pregnancy. This led to prompt resolution of her vomiting and improvement of her reflux symptoms \[[@B63]\]. El Younis et al. also reported two cases in which first-trimester patients with severe HG required intravenous fluid replacement. Rapid improvement of the HG was observed with complete resolution of all symptomatology after using of erythromycin therapy orally, which possibly suggests a new therapeutic modality for similar patients \[[@B64]\]. On the other hand, omeprazole is not licensed for use in pregnancy and ought to be used with caution although experience from case-control and observational studies has not revealed any increase in congenital malformations or pregnancy complications \[[@B65]\]. Large-scale studies were not performed. However, the above case reports could verify that the eradication of*H. pylori* might relieve the symptoms of HG.

4.2. Interpretation {#sec4.2}
-------------------

This meta-analysis has some limitations to be acknowledged. Firstly, our meta-analysis only focused on papers published in the English language and might miss some eligible studies that were unpublished in other languages. Secondly, the articles identified were limited to those openly published up to March 2014, and it is possible that some related published or unpublished studies that might meet the inclusion criteria were missed. Finally, despite using a precise literature searching strategy to identify eligible studies, it is possible that a few studies meeting the inclusion criteria were not included, resulting in any inevitable bias, though the funnel plots and Egger\'s tests failed to show any significant publication bias.

5. Conclusion {#sec5}
=============

In conclusion, our meta-analysis suggested that there was a strong association between*H. pylori* infection and HG, allowing us to conclude that*H. pylori*should, therefore, be considered as one of the risk factors of HG. Screening for*H. pylori* should be added to the investigations for HG, especially in the developing countries. Appropriate therapeutic regimens for eradication of*H. pylori* could be considered to relieve the symptoms of HG in some intractable cases.
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###### 

Characteristics of studies on *H. pylori* infection in HG cases and controls.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author, year                Study design      Country       Sample size   HG definition                                        Detection method\                                    Gestational age when included in the study   Sources of pregnant women
                                                                                                                                       of *H. pylori*                                                                                    
  --------------------------------- ----------------- ------------- ------------- ---------------------------------------------------- ---------------------------------------------------- -------------------------------------------- ---------------------------
  Frigo, 1998 \[[@B16]\]            Case-control      Austria       234           Vomiting \>3 times/day\                              Serum IgG antibodies by FEI                          ---                                          ---
                                                                                  weight loss \>3 kg\                                                                                                                                    
                                                                                  ketonuria                                                                                                                                              

                                                                                                                                                                                                                                         

  Perez-Perez, 1999 \[[@B18]\]      Case-control      USA           89            Vomiting \>3 times/day\                              Serum cagA by ELISA                                  ---                                          ---
                                                                                  weight loss \>3 kg\                                                                                                                                    
                                                                                  ketonuria                                                                                                                                              

                                                                                                                                                                                                                                         

  Koćak, 1999 \[[@B17]\]            Case-control      Turkey        211           Vomiting \>3 times/day\                              Serum IgG antibodies by FEI                          7--16 weeks                                  141 Primigravida\
                                                                                  ketonuria                                                                                                                                              70 Multigravida

                                                                                                                                                                                                                                         

  Hayakawa, 2000 \[[@B19]\]         Case-control      Japan         63            Nausea and vomiting in first trimester               Serum IgG antibodies by ELISA                        The first trimester                          ---

                                                                                                                                                                                                                                         

  Sahin, 2000 \[[@B20]\]            Case-control      Turkey        120           Prolonged severe vomiting\                           Serum IgG antibodies by ELISA                        ---                                          ---
                                                                                  dehydration\                                                                                                                                           
                                                                                  weight loss \>5%\                                                                                                                                      
                                                                                  ketonuria                                                                                                                                              

                                                                                                                                                                                                                                         

  Reymunde, 2001 \[[@B21]\]         Case-control      Puerto Rico   89            Daily nausea and vomiting in gestation weeks 6--16   Serum IgG antibodies not specified                   6--16 weeks                                  ---

                                                                                                                                                                                                                                         

  Kazerooni, 2002 \[[@B24]\]        Case-control      Iran          107           Vomiting \>3 times/day\                              Serum IgG antibodies by ELISA                        7--16 weeks                                  62 Primigravida\
                                                                                  weight loss \>3 kg\                                                                                                                                    45 Multigravida
                                                                                  ketonuria                                                                                                                                              

                                                                                                                                                                                                                                         

  Bagis, 2002 \[[@B23]\]            Case-control      Turkey        30            Severe HG in the first 16 weeks of pregnancy         Endoscopy with biopsy + histological examination     16 weeks                                     ---

                                                                                                                                                                                                                                         

  Erdem, 2002 \[[@B22]\]            Case-control      Turkey        86            Vomiting \>4 times/day\                              Serum IgG antibodies by ELISA                        ---                                          ---
                                                                                  weight loss \>5%\                                                                                                                                      
                                                                                  ketonuria                                                                                                                                              

                                                                                                                                                                                                                                         

  Berker, 2003 \[[@B27]\]           Case-control      Turkey        240           Vomiting \>3 times/day\                              Serum IgG antibodies by ELISA                        10--14 weeks                                 55 Primigravida\
                                                                                  weight loss \>5%\                                                                                                                                      105 Multigravida
                                                                                  ketonuria                                                                                                                                              

                                                                                                                                                                                                                                         

  Jacobson, 2003 \[[@B26]\]         Case-control      Canada        206           Vomiting \>3 times/day\                              Serum IgG antibodies by ELISA                        7--19 weeks                                  ---
                                                                                  weight loss\                                                                                                                                           
                                                                                  ketonuria                                                                                                                                              

                                                                                                                                                                                                                                         

  Salimi-Khayati, 2003 \[[@B25]\]   Case-control      Iran          108           Vomiting \>3 times/day\                              Serum IgG antibodies by ELISA                        6--16 weeks                                  93 Primigravida\
                                                                                  weight loss \>5%\                                                                                                                                      15 Multigravida
                                                                                  ketonuria                                                                                                                                              

                                                                                                                                                                                                                                         

  Karaca, 2004 \[[@B31]\]           Case-control      Turkey        146           Vomiting \>3 times/day\                              Serum IgG antibodies by FEI                          ---                                          ---
                                                                                  weight loss \>5%\                                                                                                                                      
                                                                                  ketonuria                                                                                                                                              

                                                                                                                                                                                                                                         

  Cevrioglu, 2004 \[[@B30]\]        Case-control      Turkey        124           Vomiting \>3 times/day\                              Serum IgG antibodies by ELISA                        The first 16 weeks                           ---
                                                                                  weight loss \>5%\                                                                                                                                      
                                                                                  ketonuria                                                                                                                                              

                                                                                                                                                                                                                                         

  Xia, 2004 \[[@B29]\]              Case-control      China         172           Vomiting \>3 times/day\                              Serum specific IgG antibodies and CagA by ELISA      7--16 weeks                                  172 Multigravida
                                                                                  weight loss \>3 kg\                                                                                                                                    
                                                                                  ketonuria                                                                                                                                              

                                                                                                                                                                                                                                         

  Jamal, 2004 \[[@B28]\]            Case-control      Iran          94            Vomiting \>3 times/day\                              Serum IgG antibodies by ELISA                        7--16 weeks                                  49 Primigravida\
                                                                                  weight loss \>3 kg\                                                                                                                                    45 Multigravida
                                                                                  ketonuria                                                                                                                                              

                                                                                                                                                                                                                                         

  Lee, 2005 \[[@B32]\]              Cross-sectional   USA           82            Vomiting \>3 times/day\                              Serum IgG antibodies by ELISA                        ---                                          ---
                                                                                  weight loss \>5%\                                                                                                                                      
                                                                                  ketonuria                                                                                                                                              

                                                                                                                                                                                                                                         

  Karadeniz, 2006 \[[@B34]\]        Case-control      Turkey        60            Vomiting \>3 times/day\                              Serum IgG antibodies by ELISA                        8--14 weeks                                  ---
                                                                                  weight loss \>5%\                                                                                                                                      
                                                                                  ketonuria                                                                                                                                              

                                                                                                                                                                                                                                         

  Özcimen, 2006 \[[@B33]\]          Cross-sectional   Turkey        140           Vomiting \>3 times/day\                              Serum IgG antibodies by ELISA                        ---                                          ---
                                                                                  weight loss \>3 kg\                                                                                                                                    
                                                                                  ketonuria                                                                                                                                              

                                                                                                                                                                                                                                         

  Tuncel, 2006 \[[@B35]\]           Case-control      Turkey        138           Vomiting \>3 times/day\                              Serum IgG antibodies by ELISA                        ---                                          ---
                                                                                  weight loss \>3 kg\                                                                                                                                    
                                                                                  ketonuria                                                                                                                                              

                                                                                                                                                                                                                                         

  Hatziveis, 2007 \[[@B38]\]        Case-control      Greece        110           Vomiting \>3 times/day\                              Serum IgG antibodies by ELISA                        8--14 weeks                                  39 Primigravida\
                                                                                  weight loss \>3 kg\                                                                                                                                    71 Multigravida
                                                                                  ketonuria                                                                                                                                              

                                                                                                                                                                                                                                         

  Güney, 2007 \[[@B37]\]            Case-control      Turkey        60            Vomiting \>4 times/day\                              Serum IgG antibodies not specified                   7--12 weeks                                  ---
                                                                                  weight loss \>5%\                                                                                                                                      
                                                                                  ketonuria\                                                                                                                                             

                                                                                                                                                                                                                                         

  Aytac, 2007 \[[@B36]\]            Case-control      Turkey        107           Vomiting \>3 times/day\                              Stool antigen by ELISA                               8--13 weeks                                  ---
                                                                                  weight loss \>5%\                                                                                                                                      
                                                                                  ketonuria                                                                                                                                              

                                                                                                                                                                                                                                         

  Sandven, 2008 \[[@B39]\]          Case-control      Norway        488           ICD-9 Code 643.1                                     Serum IgG antibodies by EIA                                                                        

                                                                                                                                                                                                                                         

  Mansour, 2009 \[[@B40]\]          Case-control      Egypt         100           Vomiting \>3 times/day\                              Serum IgG antibodies by ELISA                        10--16 weeks                                 67 Primigravida\
                                                                                  weight loss\                                                                                                                                           33 Multigravida
                                                                                  ketonuria                                                                                                                                              

                                                                                                                                                                                                                                         

  Guven, 2011 \[[@B5]\]             Cross-sectional   Turkey        80            Vomiting \>3 times/day\                              Serum IgG antibodies by ELISA                        7--12 weeks                                  ---
                                                                                  weight loss \>5%\                                                                                                                                      
                                                                                  ketonuria\                                                                                                                                             
                                                                                  dehydration                                                                                                                                            

                                                                                                                                                                                                                                         

  Mansour, 2011 \[[@B4]\]           Case-control      Egypt         160           Vomiting \>3 times/day\                              Serum IgG antibodies by ELISA                        10--16 weeks                                 ---
                                                                                  weight loss \>3 kg\                                                                                                                                    
                                                                                  ketonuria                                                                                                                                              

                                                                                                                                                                                                                                         

  Bezircioğlu, 2011 \[[@B3]\]       Case-control      Turkey        72            Vomiting \>4 times/day\                              Stool antigen by ELISA                               10--14 weeks                                 ---
                                                                                  weight loss ≥3 kg ketonuria                                                                                                                            

                                                                                                                                                                                                                                         

  Epstein, 2012 \[[@B41]\]          Case-control      USA           82            Met the diagnosis of hyperemesis                     Serum IgG antibodies by ELISA                        ---                                          ---

                                                                                                                                                                                                                                         

  Vikanes, 2013 \[[@B43]\]          Case-control      Norway        170           Long-lasting nausea and vomiting, weight loss,\      Serum IgG antibodies and CagA and VacA by EIA        17th and 22nd                                ---
                                                                                  electrolyte disturbances                                                                                                                               

                                                                                                                                                                                                                                         

  Güngören, 2013 \[[@B42]\]         Case-control      Turkey        140           Vomiting 3 times/day\                                Serum IgG antibodies by ELISA                        Below the 20th week                          ---
                                                                                  weight loss\                                                                                                                                           
                                                                                  ketone                                                                                                                                                 

                                                                                                                                                                                                                                         

  Shaban, 2014 \[[@B6]\]            Case-control      Egypt         100           Vomiting \>3 times/day\                              Serum IgG antibodies by membrane-based immunoassay   5--12 weeks                                  36 Primigravida\
                                                                                  weight loss \>5% or 3 kg\                                                                                                                              64 Multigravida
                                                                                  ketonuria                                                                                                                                              
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

HP: *Helicobacter pylori*; HG: hyperemesis gravidarum; FEI: fluorescent enzyme immunoassay; EIA: enzyme immunoassay; ELISA: enzyme-linked immunosorbent assay.

###### 

Statistical analysis of studies on the rate of *H. pylori* infection in HG cases and non-HG controls.

  First author, year                Number of cases   Number of controls   Number of cases with HP (+), *n* (%)   Number of controls with HP (+), *n* (%)   OR (95% CI)
  --------------------------------- ----------------- -------------------- -------------------------------------- ----------------------------------------- ------------------------
  Frigo, 1998 \[[@B16]\]            105               129                  95 (90.5)                              60 (46.5)                                 10.93 (5.22, 22.85)
  Perez-Perez, 1999 \[[@B18]\]      42                47                   8 (19.1)                               12 (25.5)                                 0.69 (0.25, 1.89)
  Koćak, 1999 \[[@B17]\]            95                116                  87 (91.5)                              52 (44.8)                                 13.38 (5.95, 30.13)
  Hayakawa, 2000 \[[@B19]\]         34                29                   18 (52.9)                              6 (20.6)                                  4.31 (1.40, 13.25)
  Sahin, 2000 \[[@B20]\]            60                60                   37 (61.7)                              32 (53.3)                                 1.41 (0.68, 2.91)
  Reymunde, 2001 \[[@B21]\]         45                44                   40 (89.0)                              3 (7.0)                                   109.33 (24.49, 488.12)
  Kazerooni, 2002 \[[@B24]\]        54                53                   44 (81.5)                              29 (54.7)                                 3.64 (1.52, 8.73)
  Bagis, 2002 \[[@B23]\]            20                10                   19 (95.0)                              5 (50.0)                                  19.00 (1.79, 201.68)
  Erdem, 2002 \[[@B22]\]            47                39                   40 (85.1)                              25 (64.1)                                 3.20 (1.14, 9.02)
  Berker, 2003 \[[@B27]\]           80                80                   56 (70.0)                              49 (61.2)                                 1.48 (0.77, 2.85)
  Jacobson, 2003 \[[@B26]\]         53                153                  19 (35.7)                              45 (29.7)                                 1.34 (0.69, 2.60)
  Salimi-Khayati, 2003 \[[@B25]\]   54                54                   48 (88.9)                              22 (40.7)                                 11.64 (4.25, 31.87)
  Karaca, 2004 \[[@B31]\]           56                90                   46 (82.1)                              58 (64.4)                                 2.54 (1.13, 5.70)
  Cevrioglu, 2004 \[[@B30]\]        27                97                   23 (85.2)                              71 (73.2)                                 2.11 (0.66, 6.67)
  Xia, 2004 \[[@B29]\]              72                100                  64 (88.9)                              45 (45.0)                                 9.78 (4.25, 22.51)
  Jamal, 2004 \[[@B28]\]            39                55                   26 (66.7)                              23 (41.8)                                 2.78 (1.18, 6.54)
  Lee, 2005 \[[@B32]\]              40                42                   26 (65.0)                              28 (66.7)                                 0.93 (0.37, 2.31)
  Karadeniz, 2006 \[[@B34]\]        31                29                   21 (67.7)                              23 (79.3)                                 0.55 (0.17, 1.77)
  Özcimen, 2006 \[[@B33]\]          70                70                   35 (50.0)                              33 (47.1)                                 1.12 (0.58, 2.18)
  Tuncel, 2006 \[[@B35]\]           50                88                   48 (96.0)                              73 (82.9)                                 4.93 (1.08, 22.54)
  Hatziveis, 2007 \[[@B38]\]        25                85                   14 (56.0)                              41 (48.2)                                 1.37 (0.56, 3.35)
  Güney, 2007 \[[@B37]\]            25                20                   20 (80.0)                              10 (50.0)                                 4.00 (1.07, 14.90)
  Aytac, 2007 \[[@B36]\]            52                55                   22 (42.3)                              22 (40.0)                                 1.10 (0.51, 2.38)
  Sandven, 2008 \[[@B39]\]          244               244                  105 (43.0)                             58 (23.8)                                 2.42 (1.64, 3.57)
  Mansour, 2009 \[[@B40]\]          50                50                   42 (84.0)                              18 (36.0)                                 9.33 (3.60, 24.17)
  Guven, 2011 \[[@B5]\]             40                40                   32 (80.0)                              14 (35.0)                                 7.43 (2.70, 20.42)
  Mansour, 2011 \[[@B4]\]           80                80                   71 (88.8)                              24 (30.0)                                 18.41 (7.93, 42.74)
  Bezircioğlu, 2011 \[[@B3]\]       36                36                   8 (22.2)                               1 (2.8)                                   10.00 (1.18, 84.78)
  Epstein, 2012 \[[@B41]\]          23                59                   16 (69.6)                              38 (64.4)                                 1.26 (0.45, 3.56)
  Vikanes, 2013 \[[@B43]\]          62                108                  38 (61.3)                              67 (62.0)                                 0.97 (0.51, 1.84)
  Güngören, 2013 \[[@B42]\]         90                50                   75 (83.3)                              30 (60.0)                                 3.33 (1.51, 7.36)
  Shaban, 2014 \[[@B6]\]            50                50                   46 (92.0)                              28 (56.0)                                 9.04 (2.82, 28.95)

HG: hyperemesis gravidarum; OR: odds ratio; CI: confidence interval.

###### 

Subgroup analysis of the prevalence of *H. pylori*infection in HG cases versus controls.

  Subgroup            Number of studies   Cases with HP (+)   Controls with HP (+)   OR \[95% CI\]            *P*       *Z*    Tests of heterogeneity                  
  ------------------- ------------------- ------------------- ---------------------- ------------------------ --------- ------ ------------------------ ---- --------- ------
  Region                                                                                                                                                                
   Asia               20                  769/1017            593/1121               3.27 \[2.18, 4.91\]      \<0.001   5.71   68.04                    19   \<0.001   72.1
   North America      5                   109/203             28/345                 2.33 \[0.63, 8.62\]      0.205     1.27   36.55                    4    \<0.001   89.1
   Europe             3                   157/331             166/437                1.55 \[0.83, 2.91\]      0.170     1.37   6.18                     2    0.046     67.6
   Africa             3                   159/180             70/180                 12.38 \[7.12, 21.54\]    \<0.001   8.91   1.47                     2    0.479     0
   Oceania            1                   95/105              60/129                 3.34 \[2.32, 4.81\]      \<0.001   6.35   0.00                     0    ---       ---
  Year                                                                                                                                                                  
   1996--2000         5                   245/336             162/381                3.66 \[1.17, 11.48\]     0.026     2.23   35.41                    4    \<0.001   88.7
   2001--2005         12                  451/587             403/817                3.89 \[2.10, 7.21\]      \<0.001   4.32   57.01                    11   \<0.001   80.7
   2006--2010         8                   307/547             278/641                2.01 \[1.15, 3.49\]      0.014     2.47   24.07                    7    0.001     70.9
   2011--2014         7                   286/381             202/423                4.41 \[1.72, 11.29\]     0.002     3.09   39.71                    6    \<0.001   84.9
  HP testing method                                                                                                                                                     
   HpIgGAb            29                  1240/1743           1017/2161              3.32 \[2.28, 4.84\]      \<0.001   6.25   158.05                   28   \<0.001   82.3
   HpSA               7                   124/300             124/435                1.88 \[1.33, 2.65\]      0.0004    3.57   9.50                     6    0.091     47.4
   HpDNA PCR          2                   45/124              10/79                  5.87 \[2.47, 13.93\]     \<0.001   4.02   0.63                     1    0.43      0
   HpIgAAb            1                   13/27               40/97                  1.32 \[0.56, 3.12\]      0.52      0.64   0.00                     0    ---       ---
   HpIgMAb            1                   6/90                0/50                   7.77 \[0.43, 140.84\]    0.17      1.39   0.00                     0    ---       ---
   histologically     1                   19/20               5/10                   19.00 \[1.79, 201.68\]   0.01      2.44   0.00                     0    ---       ---
  All studies         32                  1289/1851           1045/1217              3.34 \[2.32, 4.81\]      \<0.001   6.51   167.81                   31   \<0.001   81.5

HP:*Helicobacter pylori*; HG: hyperemesis gravidarum; OR: odds ratio; CI: confidence interval; df: degrees of freedom; HpIgGAb: *H. pylori* IgG antibodies; HpIgAAb: *H. pylori* IgA antibodies; HpIgMAb: *H. pylori* IgM antibodies; HpSA: *H. pylori *stool antigen; Hp DNA PCR: *H. pylori* genome by PCR.

###### 

The infection rate of CagA- or VacA-positive *H. pylori* in HG cases and controls.

  First author, year         Region   Number of cases   Number of controls   Number of cases with CagA- and/or VacA-positive *H. pylori*, *n* (%)   Number of controls with CagA- and/or VacA-positive *H. pylori*, *n* (%)   OR (95% CI)
  -------------------------- -------- ----------------- -------------------- ---------------------------------------------------------------------- ------------------------------------------------------------------------- ---------------------
  Xia, 2004 \[[@B29]\]       Asia     72                100                  50 (69.4%)                                                             14 (14%)                                                                  13.96 (6.56, 29.71)
  Vikanes, 2013 \[[@B43]\]   Europe   62                108                  21 (33.9%)                                                             44 (40.8)                                                                 0.75 (0.39, 1.43)

CagA: cytotoxin-associated gene A product; VacA: vacuolating cytotoxin A; HG: hyperemesis gravidarum; OR: odds ratio; CI: confidence interval.
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